Hiv infection, post-exposure prophylaxis

Author:Prof. Dr. med. Peter Altmeyer

All authors of this article

Last updated on: 29.10.2020

Dieser Artikel auf Deutsch

Synonym(s)

Needlestick injuries; PEP

Requires free registration (medical professionals only)

Please login to access all articles, images, and functions.

Our content is available exclusively to medical professionals. If you have already registered, please login. If you haven't, you can register for free (medical professionals only).


Requires free registration (medical professionals only)

Please complete your registration to access all articles and images.

To gain access, you must complete your registration. You either haven't confirmed your e-mail address or we still need proof that you are a member of the medical profession.

Finish your registration now

DefinitionThis section has been translated automatically.

Recommended procedure after cut or stab wounds from HIV-contaminated material or unprotected sexual contact with HIV-infected persons. See also HIV infection. The effectiveness of PEP is largely dependent on the time between exposure and the start and duration of drug administration and also on the choice of medication. At least part of the effectiveness of PEP is based on the development of a competent cellular immune response protected by the drugs.

General informationThis section has been translated automatically.

  • Remember! The average risk of HIV infection after percutaneous exposure to the blood of HIV-infected persons is about 0.3% according to the data available to date; i.e. on average, one in 330 exposures leads to HIV infection. In contrast, the average risk of infection after exposure to mucous membranes and after exposure to inflammatory changed skin parts is around 0.03% (one HIV infection for 3300 exposures). In all cases, individual differences are determined by the amount of infectious blood, the virus concentration and the duration of exposure.

  • Notice! HIV-PEP should be started as early as possible after exposure. The best results are expected if prophylaxis is started within 24 hours, or even better within 2 hours. If there are already more than 72 hours between exposure and the possible start of prophylaxis, prophylaxis can no longer be recommended according to the current state of knowledge (exceptions see above). Alternatively, HIV monitoring (HIV antibody tests e.g. 6 and 12 weeks after exposure, in case of clinical symptoms possibly HIV-PCR) can be offered and, if necessary, an early therapy can be considered if there is evidence of viremia.

  • According to the current state of knowledge, exposure to HIV is assumed to occur in:
    • injury with HIV-contaminated instruments or injection equipment
    • Wetting of open wounds and mucous membranes with HIV-contaminated fluids
    • unprotected sexual intercourse with a person infected with HIV
    • use of HIV-contaminated injection equipment and
    • Transfusion of HIV-contaminated blood or blood products.
  • Probably injuries to hollow needles are more dangerous than surgical needles. Transmission of infection must also be considered after criminal attacks with possibly infectious weapons or objects (stabbing tools, etc.) as well as injuries to several people involved.
  • Occupational HIV transmission has so far only occurred via blood or virus concentrate (virus culture), especially in the case of:
    • Stab and cut injuries
    • Contact of infectious materials with an open wound or non-intact (damaged) skin of the exposed person
    • Mucosal exposure (including blood splashes in the eye).

Note(s)This section has been translated automatically.

The following measures help to protect against contamination:
  • No recapping of protective caps on used needles!
  • Orderly, well thought-out and concentrated working method for activities involving injuries.
  • Use of safety needles (Blunt-Needles) for blood collection and indwelling cannulae.
  • Use of shatterproof and puncture-proof disposal containers for used cannulas and other disposable materials at the place of handling or take the containers with you at every corresponding intervention (avoid overfilling!).
  • Wear protective gloves against possible contact with infectious material such as blood, saliva, etc. (also applies to cleaning and disinfection measures including instrument reprocessing).
  • Use protective goggles, if necessary also closed at the sides, if there is a risk of splashing infectious material into the eye (e.g. during bronchoscopy, intubation, transurethral catheterisation, childbirth, dental treatment, working with plasma / serum / liquor).
  • Medical personnel should be vaccinated against HBV. HBV vaccination must be offered free of charge to all employees at risk of infection during recruitment and occupational health examinations. The same applies to non-medical personnel, including those from external companies, who perform cleaning and disposal services in work areas where there is a risk of infection.

TablesThis section has been translated automatically.

To assess the concrete risk of infection after HIV exposure and to clarify a possible drug resistance of HIV, the following questions should be answered:

  • When did the possible contact with HIV take place?

  • From which index person does the material come?

  • How was HIV possibly transmitted? (e.g. through hollow cannulas? through mucous membrane contact?)

  • How deep are existing injuries (always only after bleeding induction and antiseptic)? Were blood vessels opened?

  • Does the injured instrument bear traces of contamination with blood?

  • Is the index person demonstrably infected or how likely is an HIV infection?

  • At what stage of HIV disease (clinical manifestation, CD4 cell count) is the index person?

  • How high is the current viremia of the index person measured by the HIV-RNA copies/ml?

  • Is the index person treated with antiretroviral drugs? If so, with which drugs over which period of time?

  • Are resistances known?

  • What other measures have been taken so far?


Exposure

PEP Recommendation

Percutaneous injury with hypodermic needle or other hollow needle (body fluid with high virus concentration: blood, cerebrospinal fluid, puncture material, organ material, virus culture material)

Recommend PEP

Deep injury (mostly cuts), visible blood

Strongly recommend PEP

Needle after intravenous injection

Strongly recommend PEP

Superficial injury (e.g. with surgical needle)

Offer PEP

Exception if necessary, if index patient has AIDS or a high concentration of HIV

Recommend PEP

Contact of mucous membrane or injured/damaged skin with fluids of high virus concentration

Offer PEP

Percutaneous contact with body fluids other than blood (such as urine or saliva)

Do not recommend PEP

Contact of intact skin with blood (even with high virus concentration)

Do not recommend PEP

Skin or mucous membrane contact with body fluids such as urine and saliva

Do not recommend PEP


Exposure

PEP Recommendation

Transfusion of blood preserves containing HIV or preservation of blood products or organs with a high probability of containing HIV

Strongly recommend PEP

Unprotected insertive or receptive vaginal or anal intercourse (e.g. as a result of a burst condom) with an HIV-infected person

PEP recommended unless index subject is under stable HAART (VL< 50 copies for at least 6 months)

Use of HIV-contaminated injecting equipment by several drug users together or consecutively

Strongly recommend PEP

unprotected oral sexual intercourse involving the ingestion of semen from the HIV-infected partner into the mouth

Offer PEP only in the presence of additional risk factors - e.g. ulcers, mouth injuries

kissing and other sexual practices without sperm/blood-mucosal contact and S/M practices without blood-to-blood contact

Do not recommend PEP

Injury to used syringe equipment for the injection of drugs, medication or insulin

Do not recommend PEP


Combination partner →

Ritonavir (Kaletra: 2 times 400/100 mg)

Zidovudine (Retrovir: 2 times 250 mg)

Tenofovir (Viread: 1 time 300 mg)

Efavirenz* (Sustiva/ Stocrin: 1mal 600 mg)

RTI ↓

Tenofovir + emtricitabine (Truvada: 1 time 300/200 mg)

probable advantage: rapid onset of effect

possible

not useful

possible

Zidovudine + lamivudine (Combivir: 2 times 300/150 mg)

possible

not useful

possible

possible

Duration of treatment: Prophylaxis should be carried out for four weeks. Longer treatment periods may be considered if there has been massive contamination and/or the time between exposure and the start of prophylaxis is longer than 36-48 hours (expert consultation!)

  • Prophylaxis modification: A modification of these prophylaxis schemes should always be considered if the index person has been antiretrovirally pre-treated or has a detectable viral load under antiretroviral treatment. The general guidelines for modification are the rules of sequential combination therapy of HIV infection:

    • if possible, use of at least two drugs with which the index patient has not been treated before

    • Consideration of known cross-resistance

    • in index patients with NNRTI pre-treatment and virological failure as well as in patients with virological failure pre-treated with pro¬tease inhibitors, a boosted protease inhibitor (e.g. lopinavir in fixed combination with ritonavir [Kaletra]) should be preferred.

    • In index patients with known multidrug-resistant virus, the use of newer drugs such as darunavir (Prezista) and enfurvitide (Fuzeon) for post-exposure prophylaxis may also be considered.

  • The combination to be administered in individual cases should then additionally be based on the current status of therapy recommendations, as summarised with findings on side effects and interactions or on possible late effects to be expected, e.g. in the German-Austrian consensus recommendations on antiretroviral therapy. In these cases, HIV-PEP should be carried out in cooperation with a centre for HIV therapy or a physician experienced in HIV therapy. In case of uncertainty regarding the combination of drugs, however, every HIV-PEP should be started with standard prophylaxis!

  • Loss of time results in a reduced protective effect of PEP! If the suggested medication is not immediately available, other proven and immediately available medication can be used, e.g. Stavudine instead of Tenofovir or Zidovudine, Didanosine instead of Emtricitabine or Lamivudine (but no combination of Zidovudine + Stavudine or Didanosine + Stavudine, Nelfinavir (unboosted), Indinavir (boosted or unboosted) or Saquinavir (only boosted) instead of Lopinavir/ritonavir.


Standard drugs

Alternative drugs

Tenofovir, zidovudine

Stavudine (Zerit: 2 times 40 mg)*

emtricitabine, lamivudine

Didanosine (Videx: 1 x 400 mg)*

lopinavir/ritonavir

Nelfinavir**, Indinavir**, Saquinavir (Invirase:, 2 times 1000 mg + 2 times 100 mg ritonavir), Fosamprenavir (Telzir: 2 times 700 mg + 2 times 100 mg ritonavir)

Duration of treatment: Prophylaxis should be carried out for four weeks. Longer treatment periods may be considered if there has been massive contamination and/or the time between exposure and the start of prophylaxis is longer than 36-48 hours (expert consultation!)


  • Current knowledge on pre- and clinical data on antiretroviral substances in pregnancy must be obtained and reviewed. At present, no substance can be classified as completely harmless for both treatment and prophylaxis. Since zidovudine and lamivudine have the most extensive clinical experience to date, the standard PEP for a pregnant woman should contain these drugs, e.g. in the form of a combination of:

    • zidovudine + lamivudine + lopinavir/rit (Combivir 2 times/day 300/150 mg + Kaletra 2 times/day 400/100 mg).

  • As far as investigated, all antiretroviral drugs can be detected to a relevant extent in breast milk when taken. In the case of post-exposure combination therapy during the breastfeeding period, a breastfeeding break or weaning is therefore recommended, at least for the affected period.

Authors

Last updated on: 29.10.2020